地榆升白片治疗病毒性肝炎白细胞减少的临床研究

发布时间：2018-06-21 14:28

本文选题：地榆升白片 + 病毒性肝炎　；参考：《中外医疗》2016年32期

【摘要】：目的探析采取地榆升白片治疗病毒性肝炎所致白细胞减少的临床效果。方法方便选取该院2008年5月—2015年10月收治的51例病毒性肝炎白细胞减少患者,将其随机分为治疗组和对照组,两组均给予甘草类制剂、还原型谷胱甘肽保肝降酶等基础治疗,治疗组26例,加地榆升白片口服,对照组25例,加利可君片口服,比较两组治疗前后白细胞计数改善情况及效果。结果治疗组总有效率92.31%与对照组68.0%比较差异有统计学意义,P0.05;治疗2周后,治疗组白细胞计数(3.84±0.78)×109/L,治疗4周后(4.02±1.01)×109/L;与对照组比较差异有统计学意义(P0.05)。结论采取地榆升白片治疗病毒性肝炎所致白细胞减少的临床效果显著优于口服利可君片,值得临床推广。
[Abstract]:Objective to explore the clinical effect of Diyu Shengbai tablet in treating leukopenia caused by viral hepatitis. Methods from May 2008 to October 2015, 51 patients with viral hepatitis leukopenia were randomly divided into treatment group and control group. Both groups were treated with licorice preparation and glutathione hepatic reductase. 26 cases in the treatment group were treated with Diyu Shengbai tablet, 25 cases in the control group and Gali Kejun tablet. The improvement and effect of leukocyte count were compared between the two groups before and after treatment. Results the total effective rate was 92.31% in the treatment group and 68.0% in the control group (P 0.05). After 2 weeks of treatment, the white blood cell count was 3.84 卤0.78 脳 10 9 / L in the treatment group and 4.02 卤1.01 脳 10 9 / L after 4 weeks treatment, and there was a significant difference between the treatment group and the control group (P 0.05%). Conclusion the clinical effect of Diyu Shengbai tablet in the treatment of leukopenia caused by viral hepatitis is significantly better than that of oral rikejun tablet, which is worth popularizing.
【作者单位】：江苏省盐城市大丰中医院中医内科;
【分类号】：R512.6;R557.1

【相似文献】